UPDATE: Oppenheimer Raises PT to $89 on Amgen
Oppenheimer reiterated its Perform rating on Amgen (NASDAQ: AMGN) and increased its price target from $85 to $89.
Oppenheimer commented, "Amgen's 3Q revenues and EPS topped both our estimate and the Street consensus. In addition, Amgen again raised its 2012 revenue and EPS guidance. We highlight weakness in Aranesp and NEUPOGEN were more than offset by growth led by Enbrel, Xgeva, Sensipar and Nplate. Overall Amgen is demonstrating leverage in the model and continues to guide to revenue growth in excess of expense increases. Amgen remains our top pick for 4Q based on anticipated dividend increase of ~30%. We also believe that data from four Phase II studies of AMG 145 at AHA in Nov-'12 could be a significant catalyst. We maintain our Perform rating based on valuation and are increasing our PT to $89/share based on comps analysis."
Amgen closed at $87.32 on Tuesday.
Latest Ratings for AMGN
|Apr 2016||BMO Capital||Initiates Coverage on||Outperform|
|Feb 2016||Citigroup||Initiates Coverage on||Neutral|
|Feb 2016||Argus Research||Maintains||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.